Kernal Bio is a venture-backed biotech company developing mRNA 2.0 immunotherapies. CEO Yusuf Erkul, M.D., M.B.A, will present the company's mRNA platform and pipeline.
Cynthia leads strategic investments at Amgen Ventures, focusing on early-stage investing and strategic engagement. She joined Amgen Ventures in 2022 from Amgen’s corporate business development group.
Edward J Benz is President and CEO Emeritus of the Dana Farber Cancer Institute and the Richard and Susan Smith Distinguished Professor of Medicine and Professor of Pediatrics.
Manfred has focused on oncology and immuno-oncology and led multidisciplinary drug discovery projects involving kinase, metabolic and epigenetic targets, as well as small- and large-molecule and antisense modalities.
Oliver Rosen is a physician-scientist with experience in biopharmaceutical oncology and hematology product development, including global clinical development, global medical affairs, translational medicine, patient advocacy and health economics.
